In summary, our study demonstrated that docetaxel-based chemohormonal therapy can reprogram tumor microenvironment in a manner that propagates T cell immunity by augmenting the DNA-cGAS/STING-IFN signaling. This evidence concerns the gene STING1 and neoplasm.